Azar Suliman
Hepatorenal disorder, a condition characterized by acute kidney injury in patients with liver disease, presents a significant challenge in the field of hepatology and nephrology. It has been associated with high mortality rates and limited treatment options. Terlipressin, a synthetic vasopressin analog, has gained attention as a potential therapeutic intervention to manage renal deterioration in hepatorenal disorder. This drug assessment explores the pharmacology, mechanism of action, clinical efficacy, safety profile, and future prospects of Terlipressin in the context of treating and protecting against renal deterioration in patients with hepatorenal disorder.
इस लेख का हिस्सा
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu 